Pharmacokinetics of once-daily darunavir/ritonavir in HIV-1-infected pregnant women.

H M CrauwelsThomas N KakudaB RyanC ZorrillaO O OsiyemiS YasinK BrownP VerbovenV HillewaertB Baugh

Published in: HIV medicine (2016)

Total darunavir exposure decreased during pregnancy, but the decrease was less for unbound (active) darunavir. These changes are not considered clinically relevant. Darunavir/ritonavir 800/100 mg qd may therefore be a treatment option for HIV-1-infected pregnant women.

Keyphrases

antiretroviral therapy
hiv infected patients
hiv infected
pregnant women
human immunodeficiency virus
pregnancy outcomes
physical activity
combination therapy